Brent Saunders describes a recent deal Bausch + Lomb has made in dry eye disease and his goal to push further into retinal diseases as well.

Rachel Haurwitz describes recent data and the durability profile of Caribou’s allo CAR-T as the company plans to discuss a pivotal with FDA.

Chris Heery describes the process relating to bridging therapy that enabled a partial clinical hold to lift.

Fabian Gerlinghaus walks us through how the Cell Shuttle is designed to improve the time and cost of manufacturing cell therapies.

Seth Ettenberg describes safety, imaging, and efficacy takeaways from the 12-patient study.

Alex Sapir explains a tweak in the clinical trial population that allowed the trial to resume.

Josh Cohen and Justin Klee discuss the launch of RELYVRIO, the PHOENIX P3 trial, and reflect on the roller coaster of the last year.

Reenie McCarthy describes how her company focuses on mitochondria to treat disease and discusses regulatory and clinical learnings.

Michelle Werner explains the science behind how Alltrna is trying to harness transfer RNA to develop therapies for stop codon diseases.

Andrew Obenshain describes key metrics bluebird is seeing early in the launch of two of its gene therapies on its Q2 earnings day.

Jay Luly goes in depth on antiviral drug development and discusses his company’s efforts to try to develop the first therapeutic for RSV.

Gilmore O’Neill is working to inject stability and focus at Editas as it aims to execute on both ex-vivo and in-vivo crispr gene therapies.

Albert Bourla discusses Q2 earnings, the Seagen deal, Pfizer’s capacity for more deals, GLP-1s, and an update on the NC tornado damage.

Mark Enyedy discusses how the launch of the antibody-drug conjugate Elahere in platinum resistant ovarian cancer is progressing.

Laurent Levy talks about his company’s nanoparticle technology, a recent deal with Janssen, and the state of European biotech.

Al Collinson of TheracosBio discusses his plan to sell the SGLT2 inhibitor Brenzavvy for a deeply discounted price.

Paul Biondi provides context on today’s news that Flagship and Pfizer will be partnering on developing ten new programs.

Chief Therapeutics Officer Iris Grossman describes how Eleven’s screening tech might help discover the next delivery vehicle for RNA Tx.

Ram Aiyar discusses RNA editing and the news announced Friday that his company Korro Bio is aiming to do a reverse merge to go public.

CEO Seth Ettenberg explains how BlueRock is using pluripotent stems cells to try to restore dopamine production in Parkinson’s patients.